Public Market Listing
2696HKEX
Live quotes, historical charts, and market capitalization for Shanghai Henlius Biotech are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(13 total)
13Total Assets
0Approved
5Phase 3 / Filed
8Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD20Monoclonal antibody | Rheumatoid Arthritis | |
| Phase 3 | VEGF-AMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration | |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2/3 | EGFRMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2/3 | PD-L1Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 2 | BRAF V600ESmall molecule | Non-Small Cell Lung Cancer | |
| Phase 2 | LAG-3Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | BRAF V600E + PD-1 (combination regimen)Combination | Non-Small Cell Lung Cancer | |
| Phase 1/2 | PD-L1 / TIGITMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFR x 4-1BB (CD137)Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFRAntibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.